Thursday, December 11, 2008 | | Archives | Advertising | Your Account | CHI Conferences |  Subscribe |

Industry Trends

U.S. Generic Drug Market Outlook to 2012
By Mark P. Mathieu

Since drugs with $50 billion on 2007 U.S. sales are scheduled to lose patent/exclusivity protection in 2008 – 2010, the three-year period presents formidable obstacles for the pharmaceutical industry. Marketing exclusivity … Read more

Sales Contacts
For advertising information contact: Lynn Cloonan 
Contact the Editor
PharmaWeek welcomes your feedback. Please contact Allison Proffitt for editorial inquiries.

Link to Us! 
You are welcome to link to articles on our website. Contact Allison Proffitt for details.

e-Prints & Reprints 
To post a full article from PharmaWeek or Bio-IT World on your website (not just a link), or for paper reprints, please contact:
Ashley Zander
The YGS Group
717-399-1900 ext.125

Dear Colleague,
Welcome to this week's eNewsletter covering breaking R&D news, business insights, 2009 Best Practices Awards, and personalized medicine according to AstraZeneca. 


Bringing Personalized Medicine to Cancer Patients
By Alissa Poh

At a recent roundtable hosted by AstraZeneca on the topic of personalized medicine, representatives from industry, academia, and patient advocacy groups gathered to discuss ways to translate the alluring prospects of individualized medicine into therapeutic realities.

The question was summed up by the roundtable chair, Alan Barge, AstraZeneca’s vice president for clinical oncology: “What, practically speaking, can we do to bring personalized medicine to cancer patients?”

Barge noted that personalized medicine has become a much overused term in scientific lingo, but also one that is evolving within pharma.

“We’ve undergone a major shift in our thinking [at AstraZeneca],” said Jeff Hanke, Astrazeneca’s vice president for cancer discovery. “Historically, we’d pick up journal publications, find interesting biological targets to work on, and then try to fit these targets into cancer patients down the line. Now we’re focused on identifying the relevant targets to pursue in individual cancer patients, as well as the right drugs, which is where pharma has a lot of horsepower to throw at the problem.” More


Bio-IT World's 2009 Best Practices Awards

Entry forms are now available for Bio-IT World’s 2009 Best Practices Awards program. This has long been one of our most successful programs. Last year there were 56 entries and we awarded 15 prizes at a gala dinner held during the Bio-IT World Conference & Expo in the spring. This year we are hoping to expand those numbers. 

The program is intended to spotlight companies whose use of innovative technologies is making a positive difference in biomedical R&D and drug discovery and development.

Bio-IT World is also making available a free compendium of Best Practice entries from 2008 to help ensure the lessons learned are widely spread.

Meanwhile, get started on this year’s entries. There are nine entry categories and the deadline is mid-January 2009. Full details of the entry process and the entry form are available online.

2009 Best Practices Categories:

  • Basic Research & Biological Research
  • Drug Discovery & Development
  • Clinical Trials & Research
  • Translational Medicine
  • Personalized Medicine
  • IT & Informatics
  • Knowledge Management
  • Health-IT
  • Manufacturing & Bioprocessing

All of the entries will be reviewed and ranked by a panel of experts assembled by Bio-IT World editors. Winners will be announced at a dinner ceremony held in Boston in April 2009 in conjunction with the Bio-IT World Conference & Expo. If you have questions, contact to Allison Proffitt by email or at 781-972-1345.


Genentech, Roche’s Rituxan Drug Curbs Leukemia, Study Finds
Bloomberg [Dec 11] Clinical trials show that Rituxan combined with chemotherapy slowed chronic lymphatic leukemia. More


Eli Lilly Aims for $800-Million Pill By 2010
Bloomberg & Forbes [Dec 11] The media took contrasting views of Eli Lilly’s lowered financial expectations for 2009. More


Merck To Make Generics
Forbes [Dec 11] Merck is creating a new generics division, clearly indicating the struggle Big Pharma is having over patents. More

Pharma Restricts Drug Ads
CNN Money [Dec 11] Pharma is changing its advertising strategy thanks to increased Congressional interest in drug ads, with some members arguing that current ads mislead consumers about drug safety and effectiveness. More

Merck Faces Another Tough Year
Forbes [Dec 11] Two years ago, Merck chief Richard Clark seemed to have pulled off an amazing turnaround. What happened? More



Monsanto Scientific Software Design Opportunities
Monsanto has several exciting, cutting-edge opportunities in its software design group, Technology Pipeline Solutions (TPS), which require a scientific background and an interest in software development. Join a leader in biotechnology agriculture by working to design customized software solutions for our research and development groups. Please visit and search for the following four positions: Emerging Strategies Lead, Strategic Scientist, Engagement Manager and Scientific Business Analyst.  Monsanto values diversity and is an equal opportunity employer. M/F/D/V

Director, Center For Information Technology (CIT) - National Institutes of Health  (NIH), Department of Health and Human Service
Located in Bethesda, MD. This position requires:
• High-level vision, leadership, management, and modernization of CIT programs and services.
• Strategic direction and policy development for CIT long-term operations and objectives.
• Serve as a key IT advisor to the NIH Chief Information Officer.
A TOP SECRET security clearance will be required.  More job detail is found at: under the Executive Jobs section.Or contact Ms.Winnie Garner at  Applications must be received ELECTRONICALLY by (11:59 p.m.), December 17, 2008.  DHHS and NIH are Equal Opportunity Employers

More Life Science Jobs ~ Add a Job Listing



Electronic Laboratory Notebooks -
 28th to 29th January 2009
ALA presents LabAutomation 2009,
 January 24-28 

Immunogenicity for Biotechnology -
 January 26-27,2009 

Health 3.0: Next Online Generation -
 January 26-28,2009 

The BIO IT Coalition -
 January 28, 2009  

TEPR+ 2009 - Feb 1-5, 2009  

The World Health Care Congress 2nd Annual Leadership Summit 

16th International Molecular Medicine Tri-Conference -
February 25-27, 2009 

Electronic Data in Clinical Trials –
 March 11-12, 2009 

7th Annual Bio-IT World Expo – April 2009

BIO IT Coalition's 8th annual Conference -April 22, 2009 

Storage for Science Seminar Series-
See Schedule Here
Barnett Educational

Cambridge Healthtech Events   

To have your event featured here, contact Lynn Cloonan for more information.

 Email to a Friend 

That Was PharmaWeek …

Dear PharmaWeek Reader:

This issue will sadly be the last installment of Cambridge Healthtech Media Group’s PharmaWeek, at least for the foreseeable future. Our parent company CHI launched the newsletter in 2006 to provide timely business information to pharmaceutical and biotech executives, and in the hands of founding editor Malorye Allison, Laurie Sullivan, and most recently Alissa Poh, succeeded in doing just that. We particularly note the outstanding efforts of Alissa in the past few months, who delivered a series of novel and insightful reports. Until recently, we saw a very bright future for this title, but unfortunately, economic conditions dictated that we refocus our editorial and sales efforts. PharmaWeek proved to be a luxury we could not afford.

Bio-IT World continues to publish three outstanding and informative e-newsletters—Predictive Biomedicine, eCliniqua, and Bio-IT World’s Weekly Update—and we urge you to check them out if you don’t already subscribe.

We also hope that you will continue to see Alissa Poh’s byline in Bio-IT World from time to time. Readers may contact her at:

Thank you for your support of PharmaWeek and Bio-IT World. We’ll see you in the New Year.

Kevin Davies PhD
Editor-in-Chief, Bio-IT World


Life Science Webcasts from Bio-IT World and Cambridge Healthtech Media Group

Life Science Webcasts

Exploring Next-Generation Sequencing
Bio-IT World Editor-in-Chief Kevin Davies interview BGI's Laurie Goodman on the sequencing of the first Asian genome. View the webcast.

Drug Discovery, Development and Commercialization: Evolving Challenges and Opportunities
Joshua Boger, PhD, president and CEO, Vertex Pharmaceuticals Inc., delivers his keynote at the 2008 Bio-IT World Conference & Expo in Boston, April 2008.
View the Webcast Now.

Personalized Genetics: Advancements and Driving Change
Linda Avey, co-founder of 23andMe, delivers her keynote at the 2008 Bio-IT World Conference & Expo in Boston, April 30, 2008.
View the Webcast Now.

The Future of Personal Genomics
A distinguished panel of personal genomics experts discuss the future of personal genomics at the 2008 Bio-IT World Conference & Expo in Boston, April 30, 2008.  They include Dietrich Stephan (co-founder, Navigenics); George Church (Harvard Medical School);
Jeff Drazen (editor-in-chief, New England Journal Medicine); Fred Ledley (Bentley College); John Halamka (CIO, Harvard Medical School); and Linda Avey (23andMe). Bio-IT World Editor-in-Chief Kevin Davies moderates the discussion.
View the Webcast Now

Insight Pharma Reports

Stem Cells Come of Age

Considers applications of stem cell science in drug development & regenerative medicine and examines sources of funding, regulatory hurdles, the commercial outlook, and much more. More Information

Featured Content

High-Performance Computing in Life Science & Education, underwritten by SGI and Intel 

The varied collection of Bio-IT World articles and insights assembled in this BriefingON examine key trends in HPC infrastructure and how researchers are putting their best computational resources to use. Provided here are stories and lessons around the effective use of high performance computing in life science. Download the BriefingON.  

10 Secrets to Recession-Proof Your Business
Sponsored by Coupa

Read this white paper to discover 10 strategies smart companies deploy to recession-proof their business.
Leaders generally face hard choices on how to mange a company during an economic downturn and
behave in one of three ways:
• “The ostrich” - Preserve the status quo/hope for the best
• “The bull in the china shop” - Blindly cut expenses across the board
• “The fox” - Use the downturn to make your business more effective and position it for future growth.
Learn how to behave “like a fox” and use a recession as a means to pounce on emerging trends.
Download This Complimentary Paper.

Next Generation Sequencing  Learn how labs can maximize the value they receive from their next generation sequencing instruments:
sponsored by Genologics

How can labs generate value from their next generation sequencing instruments
What are the data management challenges for labs conducting next generation sequencing
What do genomics labs need to look for when evaluating lab and data management systems
How are different labs using a lab and data management system to address their data management challenges
Download Now 

To have your white paper featured here, contact Lynn Cloonan for more information.

                                Healthtech InstitutePublished by Cambridge Healthtech Institute (CHI). Copyright © 2008, all rights reserved. No material may be reproduced electronically or in print without written permission from CHI, 250 First Ave., Needham, MA 02494-2814. For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA; 17601 717-399-1900 ext.125, or email: